In October 2018, the National Test Directory (NTD) for Cancer was published.
The National Test Directory is updated each year to ensure access to the latest diagnostics and treatments. The NTD specifies which genomic tests are commissioned by the NHS in England, the clinical indication for which they apply and the technology by which the tests will be delivered.
Access to genomic services for HaemOnc patients will continue to be through your Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS).
The NE&Y GLH cover three regional SIHMDS groups:
North East Haematological Oncology Diagnostic Service
Genomic haemato-oncology diagnostics are funded centrally by NHSE and so referring Trusts will not be charged for these services if they refer testing to their designated local GLH.
Note. Non-genetic activity carried out within an SIHMDS is funded separately and will still be charged for.
The Haemato-Oncology Team
Dr Catherine Cargo
HaemOnc Lead Clinician
In order to support the interpretation of genomic data and its integration within the clinical Multi-Disciplinary Team process a series of genomic advisory boards have been established.
These are multi-disciplinary teams who analyse the more complex genomic results which arise from testing for larger numbers of gene abnormalities.
GMT Meetings
The 2020/2021 National Genomic Test Directory for rare and inherited disorders and cancer.
View Directory
